Wednesday, 13 March 2013

Pharmaceutical Industry

My recent interest in the Pharmaceutical Industry has allowed me to explore learn a great deal about the manufacturing processes and regulatory guidelines in different countries. I would like to share what i have learned about Good Manufacturing Practices(GMP) in the Pharmaceutical Industry.

 

Good Manufacturing Practices (GMP)

Guidelines and standards are important in any industry you work in but nowhere does it get updated and changed more so than in the Pharmaceutical Industry. Designing a modern, compliant pharmaceutical facility is difficult enough within a demanding and competitive industry but constantly changing standards and increasing complexity of regulations make it even tougher1.

 

 Overview

According to the World Health Organisation(WHO): “GMP or good manufacturing practice is a part of quality assurance which ensures that products are consistently produced and controlled to the quality standards appropriate to the intended use as required by the marketing authorisation.” The general guiding principle behind GMP is that quality should built into the product and not just into a finished product. So the product not only meets the final specification but has been made using the same procedures under the same conditions under the same conditions each and every time. There is a term for ensuring quality is built into the design of pharmaceutical products, Quality by Design (QbD), which is probably the hottest topic in the industry now since GSK has successfully demonstrated a continuous production process. I will have to talk more on QbD on another article and place the link here**.
This would mean that we have to control the quality of the starting materials, the facility and its systems should be top notch as well as maintaining quality of production at all stages. Apart from these, quality should be ensured during testing of the product and all materials must have adequate storage facilities.
GMP covers all aspects of manufacturing process and I am going to list out below what GMP inspectors are typically looking for:
1.                   A well-defined manufacturing process
2.                   Validated critical manufacturing steps
3.                   Suitable premises for storage and transport of materials
4.           Qualified and trained production, quality control personnel
4.                   Adequate laboratory facilities
5.                   Approved written procedures and instructions
6.                   Records all steps taken
7.                   Full traceability of product
8.                   Systems for recall and investigation of complaints

If we look at a typical project stages in the Pharmaceutical industry, we can locate the stages in which certain guidelines and regulations kick in. For example see the figure below for an overview:

Regulatory driven manufacturing requirements cover various issues including facilities design, product delivery and validation issues.

 

Regulatory Issues

Although different countries have their own regulatory bodies, the most widely used (accepted) are the FDA, EU and Japan regulations because these regions house major pharmaceutical manufacturers and represent the largest proportion of the market combined. While FDA’s current GMPs provide minimal guidance by outlining facility requirements and requirements for documentation of manufacturing procedures, the FDA also issues regulations in the code of federal register (CFR) 21. These regulations are summarised in the table below:


 
No.
CFR Regulations
21 CFR 210
Current Good Manufacturing Practices in Manufacturing, Processing, Packaging or General Holding of Drugs
21 CFR 211
Current Good Manufacturing Practices for Finished Pharmaceuticals
·  Part C
Building and Facilities
·  Part D
Equipment
21 CFR 600
General Biological Products
21 CFR 820
Quality Systems Regulations

Future Implications

GMP guideline is constantly evolving with technology to accommodate rising demand for quality and value products. The future of global pharmaceutical industry is going to be “dynamic and highly responsive to marketing and regulatory forces”1. There will be higher expectations from manufacturing facilities to keep up with economic and regulatory requirements in order to maintain flexibility, safety, value and speed to market. Good design practices will apply to all manufacturers as they try to achieve business objectives and at the same time conform to globally harmonised guidelines which address an increasingly safety and quality conscious community. 

 

Reference/Further Reading:

[1] Good Design Practices for GMP Pharmaceutical Facilities: Drugs and the pharmaceutical industry, Andrew A. Signore, Terry Jacobs Vol. 146 [2005]
[2] Good Manufacturing Practices for Pharmaceuticals: A plan for Total Quality Control, Sidney H. Willig, Murray M. Tuckerman and William S. Hatchings IV, [2nd / 3rd Edition]
[3] Modern Pharmaceutics, edited by Gilbert S. Banker and Christopher T.  Rhodes
[4] Pharmaceutical Process Validation, edited  by Bernard T. Loftus and Robert A. Nash
[5] Handbook of Pharmaceutical Granulation Technology, edited by Dilip M. Parikh
[6] Automation and Validation of Information in Pharmaceutical Processing, edited by Joseph F. deSpautz
[7] Pharmaceutical Process Engineering, Anthony J. Hickey and David Ganderton*

Thursday, 7 March 2013

Return to blogging


After a long break, I'm starting the habit of writing again. I think its important to share knowledge and findings with others, it helps one grow as a person. Who knows, one day you might influence someone's way of thinking; to be less wasteful; to THINK about the environment; to THINK about Sustainability in every aspect of their lives.

With that i hope my readers have found my past articles interesting and having some kind of influence/impart in their lives. Cannot believe that this blog has had more than 9000 visiter over the past 2 years. I guess the content has been useful to some people, whether they are doing research on the net or just reading for pleasure. I shall carry on writing whenever possible.
 

Bioenergy - Biomass Utilisation

Biomass is actually potential energy stored within itself and i believe we are not fully utilising the potential out there. Finding more about the current research progress in this field is important as i discovered recently at a workshop organised by ICES of Singapore. The Bioenergy-Biomass Utilisation workshop was held on 25-Feb 2013, organised by ICES in collaboration with A*STAR. I will try and capture key learning’s from the event. Some of the techniques discussed below could potentiall be used for future projects. Research topics discussed were:


Cultivation and characterization of a New Butanol-Acetone Producing Clostridium Species

-Asst. Prof He Jianzhong (NUS)

Molecular engineering of membrane materials and fabrication for the separation of Acetone butanol ethanol (ABE) broths produced from non-food biomass

-Prof. Neal Chung (NUS)

Enhancing plant biomass for cellulosic ethanol production

-Prof. Prakash Kumar

Developing Novel biocatalysts for cellulosic Ethanol production

-Dr Geng Anli

Next Generation Fuels: Upgrading of biomass-derived Pyrolysis Oil

-Dr. Chang Jie

Thermal degradation of biomass to produce valuable products

-Dr. Paul Sharatt

Brief intro

The workshop explored mainly 2nd generation biofuels derived from non-food crops1. This is vital to avoid the whole drama of "Food vs. Fuel" , keeping in touch with current rocketing food prices in an ever rising inflation environment. The figure below summarises the methods of obtaining biofuels from lignocellulose:














As you can see from Fig. 1 above, there are multiple ways we can make use of Lignocellulosic biomass.

Key Research Findings


  • In the generation of biofuels via biological process: A single species of Clostridium has been identified as highest yielding strain capable of producing butanol at 29% yield2.
  • Membrane based pervaporation was successfully demonstrated to yield 99.5% alcohol from fermentation broth. This membrane technology is currently being explored for commercialisation2.
  • Novel biocatalysts (enzymes from fungal strains) for biomass hydrolysis and sugar fermentation were identified and tested with Oil palm empty fruit bunch. Results show 84% conversion rate2.

Shak's Recommendation


  • I foresee many opportunities to utilise current research findings in majority of industries. For example, wood chips from logging industry, Kernels and husk leftover from corn field, not to forget; PALM Oil industry. This about the huge potential of converting wasted leftovers into useful bio-energy.
  • Encourage all interest parties from whichever industry you come from to collaborate with ICES, develop synergies between R&D and your Industry. [** Must put Disclaimer here: I do not represent ICES or any other interested party, there are research departments in most Engineering universities around the world, you may wish to sponsor their research. But if you are in Singapore, there is local collaboration between NUS/NTU and ICES which you can support too.]
  • There's potential alternate application of membrane based pervaporation to separate impurities from water to obtain Process Water, without the hassle of distillation, a major cost component in Utilities.

REFERENCE:

[2]ICES Bioenergy - Biomass Utilisation Workshop abstracts : http://www.ices.a-star.edu.sg/media/22848/Abstracts%20for%20Bioenergy_Biomass%20Utilisation%20Workshop.pdf